{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:30:35Z","timestamp":1685032235132},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["IISP 53342","IISP 53342","IISP 53342","IISP 53342"],"award-info":[{"award-number":["IISP 53342","IISP 53342","IISP 53342","IISP 53342"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1037903","APP1037903","APP1037903","APP1037903"],"award-info":[{"award-number":["APP1037903","APP1037903","APP1037903","APP1037903"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck"},{"name":"Merck"},{"name":"Merck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coronary artery bypass grafting is among the most commonly performed of all cardiovascular surgical procedures. However, graft failure due to stenosis reduces the long-term benefit of the intervention. This study asks if elevating plasma high density lipoprotein cholesterol (HDL-C) levels by inhibition of cholesteryl ester transfer protein (CETP) activity with des-fluoro-anacetrapib, an analog of the CETP inhibitor anacetrapib, prevents vein bypass-induced neointimal hyperplasia. NZW rabbits were placed on a normal chow diet or chow containing 0.14% (wt\/wt) des-fluoro-anacetrapib for 6 weeks. Bypass grafting of the jugular vein to the common carotid artery was performed 2 weeks after starting dietary des-fluoro-anacetrapib supplementation. The animals were euthanised 4 weeks post-bypass grafting. Relative to control, dietary supplementation with des-fluoro-anacetrapib reduced plasma CETP activity by 89\u2009\u00b1\u20096.9%, increased plasma apolipoprotein A-I levels by 24\u2009\u00b1\u20095.5%, increased plasma HDL-C levels by 93\u2009\u00b1\u200926% and reduced intimal hyperplasia in the grafted vein by 38\u2009\u00b1\u20096.2%. Des-fluoro-anacetrapib treatment was also associated with decreased bypass grafting-induced endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), endothelial dysfunction, and smooth muscle cell (SMC) proliferation in the grafted vein. In conclusion, increasing HDL-C levels by inhibiting CETP activity is associated with inhibition of intimal hyperplasia in grafted veins, reduced inflammatory responses, improved endothelial function, and decreased SMC proliferation.<\/jats:p>","DOI":"10.1038\/s41598-019-52510-0","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:05:29Z","timestamp":1573124729000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits"],"prefix":"10.1038","volume":"9","author":[{"given":"Ben J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Leung","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Johns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"52510_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0021-9150(01)00446-4","volume":"158","author":"M Hanyu","year":"2001","unstructured":"Hanyu, M. et al. VCAM-1 expression precedes macrophage infiltration into subendothelium of vein grafts interposed into carotid arteries in hypercholesterolemic rabbits\u2013a potential role in vein graft atherosclerosis. Atherosclerosis. 158, 313\u2013319 (2001).","journal-title":"Atherosclerosis."},{"key":"52510_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.lfs.2012.03.024","volume":"91","author":"R Cerrato","year":"2012","unstructured":"Cerrato, R. et al. Endothelin-1 increases superoxide production in human coronary artery bypass grafts. Life Sci. 91, 723\u2013728 (2012).","journal-title":"Life Sci."},{"key":"52510_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<197::AID-PATH587>3.0.CO;2-D","volume":"179","author":"LD Buttery","year":"1996","unstructured":"Buttery, L. D. et al. Explanted vein grafts with an intact endothelium demonstrate reduced focal expression of endothelial nitric oxide synthase specific to atherosclerotic sites. J Pathol. 179, 197\u2013203 (1996).","journal-title":"J Pathol."},{"key":"52510_CR4","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jss.2012.06.017","volume":"180","author":"FD Li","year":"2013","unstructured":"Li, F. D. et al. Intimal thickness associated with endothelial dysfunction in human vein grafts. J Surg Res. 180, e55\u2013e62 (2013).","journal-title":"J Surg Res."},{"key":"52510_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon, D. J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8\u201315 (1989).","journal-title":"Circulation"},{"key":"52510_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11883-009-0080-0","volume":"12","author":"AV Khera","year":"2010","unstructured":"Khera, A. V. & Rader, D. J. Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep. 12, 73\u201381 (2010).","journal-title":"Curr Atheroscler Rep."},{"key":"52510_CR7","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 371, 2382\u20132393 (2014).","journal-title":"N Engl J Med."},{"key":"52510_CR8","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/01.CIR.0000159351.95399.50","volume":"111","author":"SJ Nicholls","year":"2005","unstructured":"Nicholls, S. J. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111, 1543\u20131550 (2005).","journal-title":"Circulation"},{"key":"52510_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1096\/fj.12-212753","volume":"27","author":"EP van der Vorst","year":"2013","unstructured":"van der Vorst, E. P. et al. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J. 27, 1413\u20131425 (2013).","journal-title":"FASEB J."},{"key":"52510_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/01.ATV.0000216600.37436.cf","volume":"26","author":"C Tso","year":"2006","unstructured":"Tso, C. et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 26, 1144\u20131149 (2006).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","volume":"105","author":"LE Spieker","year":"2002","unstructured":"Spieker, L. E. et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 105, 1399\u20131402 (2002).","journal-title":"Circulation."},{"key":"52510_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","volume":"23","author":"PJ Barter","year":"2003","unstructured":"Barter, P. J. et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 23, 160\u2013167 (2003).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1161\/ATVBAHA.114.304747","volume":"35","author":"BJ Wu","year":"2015","unstructured":"Wu, B. J. et al. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit. Arterioscler Thromb Vasc Biol. 35, 628\u2013636 (2015).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1161\/ATVBAHA.117.310051","volume":"37","author":"BJ Wu","year":"2017","unstructured":"Wu, B. J. et al. Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition. Arterioscler Thromb Vasc Biol. 37, 2333\u20132341 (2017).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR15","first-page":"E894","volume":"255","author":"JH Tollefson","year":"1988","unstructured":"Tollefson, J. H., Liu, A. & Albers, J. J. Regulation of plasma lipid transfer by the high-density lipoproteins. Am J Physiol. 255, E894\u2013E902 (1988).","journal-title":"Am J Physiol."},{"key":"52510_CR16","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.1074\/jbc.275.12.9019","volume":"275","author":"MA Clay","year":"2000","unstructured":"Clay, M. A., Pyle, D. H., Rye, K. A. & Barter, P. J. Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase. J. Biol. Chem. 275, 9019\u20139025 (2000).","journal-title":"J. Biol. Chem."},{"key":"52510_CR17","first-page":"29","volume":"30","author":"F St\u00e4hler","year":"1977","unstructured":"St\u00e4hler, F., Gruber, W., Stinshoff, K. & R\u00f6schlau, P. A practical enzymatic cholesterol determination. Med. Lab. (Stuttg). 30, 29\u201337 (1977).","journal-title":"Med. Lab. (Stuttg)."},{"key":"52510_CR18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/clinchem\/25.2.325","volume":"25","author":"JK Allen","year":"1979","unstructured":"Allen, J. K., Hensley, W. J., Nicholls, A. V. & Whitfield, J. B. An enzymic and centrifugal method for estimating high-density lipoprotein cholesterol. Clin. Chem. 25, 325\u2013327 (1979).","journal-title":"Clin. Chem."},{"key":"52510_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/ATVBAHA.109.201129","volume":"30","author":"BJ Wu","year":"2010","unstructured":"Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 30, 968\u2013975 (2010).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrcardio.2016.76","volume":"13","author":"MR de Vries","year":"2016","unstructured":"de Vries, M. R., Simons, K. H., Jukema, J. W., Braun, J. & Quax, P. H. Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol. 13, 451\u2013470 (2016).","journal-title":"Nat Rev Cardiol."},{"key":"52510_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrcardio.2015.164","volume":"13","author":"K Yahagi","year":"2016","unstructured":"Yahagi, K. et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 13, 79\u201398 (2016).","journal-title":"Nat Rev Cardiol."},{"key":"52510_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jss.2016.11.020","volume":"212","author":"JY Zhang","year":"2017","unstructured":"Zhang, J. Y. et al. Local application of paeonol prevents early restenosis: a study with a rabbit vein graft model. J Surg Res. 212, 278\u2013287 (2017).","journal-title":"J Surg Res."},{"key":"52510_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jvs.2007.03.044","volume":"46","author":"K Hattori","year":"2007","unstructured":"Hattori, K. et al. Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. J Vasc Surg. 46, 116\u2013123 (2007).","journal-title":"J Vasc Surg."},{"key":"52510_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.yjmcc.2006.04.006","volume":"41","author":"T Miyake","year":"2006","unstructured":"Miyake, T. et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol. 41, 431\u2013440 (2006).","journal-title":"J Mol Cell Cardiol."},{"key":"52510_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8090-8-172","volume":"8","author":"K Jerzewski","year":"2013","unstructured":"Jerzewski, K., Ruel, M., Voisine, P., Le May, M. R. & Kulik, A. Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. J Cardiothorac Surg. 8, 172 (2013).","journal-title":"J Cardiothorac Surg."},{"key":"52510_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/ATVBAHA.115.306879","volume":"36","author":"PJ Barter","year":"2016","unstructured":"Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition is not yet dead\u2013Pro. Arterioscler Thromb Vasc Biol. 36, 439\u2013441 (2016).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Bowman, L. et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 377, 1217\u20131227 (2017).","journal-title":"N Engl J Med."},{"key":"52510_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcph.1004","volume":"58","author":"R Krishna","year":"2018","unstructured":"Krishna, R. et al. Pharmacokinetics and pharmacodynamics of anacetrapib following single doses in healthy, young Japanese and White male subjects. J Clin Pharmacol. 58, 254\u2013262 (2018).","journal-title":"J Clin Pharmacol."},{"key":"52510_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1074248414529621","volume":"19","author":"AM Gotto","year":"2014","unstructured":"Gotto, A. M. et al. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 19, 543\u2013549 (2014).","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"52510_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/ATVBAHA.111.223271","volume":"31","author":"JC Karper","year":"2011","unstructured":"Karper, J. C. et al. Toll-like receptor 4 is involved in human and mouse vein graft remodelling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol. 31, 1033\u20131040 (2011).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"52510_CR31","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.transproceed.2013.03.045","volume":"45","author":"XB Meng","year":"2013","unstructured":"Meng, X. B. et al. Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models. Transplant Proc. 45, 2553\u20132558 (2013).","journal-title":"Transplant Proc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52510-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52510-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:27:30Z","timestamp":1671290850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52510-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52510"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52510-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J. is an employee of Merck & Co, Inc. The other authors have no conflicts of interest to disclose. This work was supported by Merck & Co., Inc, the National Health and Medical Research Council (NHMRC) of Australia (Grants 482800 and 1037903) to KAR and PJB and an NHMRC Career Development Fellowship (1122854) to KLO. YS was supported by the Medical University of Graz, Doctoral College of Metabolic and Cardiovascular Disease and the Austrian Science Fund (Grant DK-MCD W1226-B18).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16183"}}